Department of Otolaryngology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, U.S.A.
Laryngoscope. 2022 May;132(5):989-998. doi: 10.1002/lary.29895. Epub 2021 Oct 12.
To compare overall survival (OS) and disease-free survival (DFS) between sentinel lymph node biopsy (SNB) and elective neck dissection (END) in the surgical management of cT1-2N0 oral cavity squamous cell carcinoma (OCSCC).
English full-text articles were searched in PubMed and Embase on May 9, 2021. Articles had to compare SNB with END in cT1-T2N0 OCSCC patients; report hazard ratios (HRs), Kaplan-Meier curves, or P-values with total number of events for survival outcomes; be from a clinical trial, cohort, or case-control study. Two reviewers reviewed articles and a third settled disagreements. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Risk of Bias in Non-randomized Studies of Interventions tool and revised Cochrane risk-of-bias tool for randomized trials were used. The generic inverse variance method with a random-effect model was used for meta-analysis.
Ten studies, five retrospective, three prospective, and two randomized controlled trials, were included (total number of patients [n] = 10,498, END n = 9102, SNB n = 1396). No significant differences were found in OS (HR = 0.92; 95% confidence interval [CI]: 0.65-1.31) or DFS (HR = 0.70; 95% CI: 0.41-1.20). Heterogeneity was not detected in pooled OS analysis (P = .18; I = 30%), but was in pooled DFS analysis (P = .003; I = 66%).
No statistically significant differences in OS or DFS were observed between SNB and END in cT1-2N0 OCSCC, suggesting that SNB might be an alternative to END in the management of early-stage, clinically node-negative OCSCC. Laryngoscope, 132:989-998, 2022.
比较口腔鳞状细胞癌(OCSCC)cT1-2N0 患者中前哨淋巴结活检(SNB)与选择性颈部清扫术(END)在手术治疗中的总生存(OS)和无病生存(DFS)。
于 2021 年 5 月 9 日在 PubMed 和 Embase 中检索英文全文文献。文章必须比较 cT1-T2N0 OCSCC 患者的 SNB 与 END;报告生存结果的危险比(HR)、Kaplan-Meier 曲线或 P 值以及总事件数;来自临床试验、队列或病例对照研究。两名审查员审查文章,第三名解决分歧。采用系统评价和荟萃分析的首选报告项目以及非随机干预研究的偏倚风险工具和修订的随机试验 Cochrane 偏倚风险工具。使用具有随机效应模型的通用倒数方差法进行荟萃分析。
纳入了 10 项研究,其中 5 项为回顾性研究,3 项为前瞻性研究,2 项为随机对照试验(共纳入患者 10498 例,END 组 n=9102,SNB 组 n=1396)。OS(HR=0.92;95%置信区间 [CI]:0.65-1.31)或 DFS(HR=0.70;95%CI:0.41-1.20)均无显著差异。OS 汇总分析中未检测到异质性(P=0.18;I²=30%),但在 DFS 汇总分析中检测到异质性(P=0.003;I²=66%)。
在 cT1-2N0 OCSCC 中,SNB 与 END 之间的 OS 或 DFS 无统计学显著差异,提示 SNB 可能是治疗临床淋巴结阴性早期 OCSCC 的 END 的替代方法。《喉镜》,132:989-998,2022。